Recently, a study revealed that combining a KRAS inhibitor with immunotherapy agents in vivo not only enhanced T-cell infiltration and activation but also depleted immunosuppressive myeloid cells and alleviated the immunosuppressive TME in PC, thereby extending the survival of an autochthonous PC mouse model (64). The gene discussed is KRAS; the disease is pachyonychia congenita.